Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
09:15am, Monday, 05'th May 2025
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago.
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 05'th May 2025
Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY ® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI ® 1Q
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
07:00am, Thursday, 01'st May 2025
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
11:06am, Monday, 28'th Apr 2025
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 22'nd Apr 2025
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a
Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm
02:03pm, Wednesday, 16'th Apr 2025
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached the
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
02:00pm, Wednesday, 16'th Apr 2025
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
11:03am, Thursday, 10'th Apr 2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) bre
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
10:55am, Thursday, 10'th Apr 2025
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
02:03pm, Tuesday, 08'th Apr 2025
NEW YORK , April 8, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breac
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
07:00am, Tuesday, 08'th Apr 2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a
Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
12:30pm, Wednesday, 02'nd Apr 2025
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
Why Shares of Axsome Therapeutics Slumped Today
01:23pm, Tuesday, 01'st Apr 2025
Shares of biopharmaceutical company Axsome Therapeutics (AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (b
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
01:06pm, Tuesday, 01'st Apr 2025
Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive. The post Axsome Therapeutics Dives Again On Its Second Big Drug Failure In
